Among patients with pathological stage IIIA who underwent curative intent surgery, 339 patients with EGFR variation–positive and 60 patients with ALK-positive NSCLC had inferior RFS than 297 patients with EGFR and ALK wild type NSCLC (median RFS was 25.2 months [95% CI, 22.6 to 30.6 months], 48.8 months [95% CI, 31.2 to 107.4 months], and 53.1 months [95% CI, 40.2 to 81.5 months] in patients with AD and EGFR variation–positive, ALK-positive, and EGFR and ALK wild type NSCLC, respectively) (eFigure 3 in Supplement 1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.